- Advanced renal cell carcinoma
- Advanced hepatocellular carcinoma
- Differentiated thyroid carcinoma
ADTRINIB
| MRP | : |
|
| Price | : | ₹2,000.00 |
| You Save | : | ₹585.00 (22.63%) |
30 Tablet(s) In A Bottle
Adtrinib Tablet is classified as a multikinase inhibitor cancer medication, containing sorafenib as its active ingredient. It is mainly prescribed for the treatment of advanced renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer), and thyroid cancer.
Adtrinib Tablet should not be used if you have an allergy to the active ingredient or any other components of the medication. If you notice skin rashes, heart issues, chest pain, bleeding problems, high blood pressure, or if you have had or are planning to undergo surgery, consult your doctor immediately. This medication is not advised for children and adolescents. Patients with diabetes should regularly check their blood sugar levels to determine if adjustments to their anti-diabetic medication are necessary to prevent low blood sugar. Your physician will conduct liver function tests and monitor fluid and electrolyte levels to quickly identify and address any potential side effects.
